Guizhou Xinbang Pharmaceutical Co., Ltd.
Simbolis: 002390.SZ
SHZ
3.89
CNYRinkos kaina šiandien
32.8887
P/E santykis
-2.3022
PEG koeficientas
7.06B
MRK kapitalizacija
- 0.01%
DIV pajamingumas
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 899.2 | 624.6 | 1776.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 3870.6 | 4011.3 | 3466.8 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 1032.7 | 935.7 | 843.4 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 3.7 | 4.7 | 4.6 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 5806.2 | 5576.4 | 6091.1 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 2671.7 | 2705.9 | 2323.2 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 607.3 | 607.3 | 605.5 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 204.4 | 217.6 | 219.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 811.7 | 825 | 825.1 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 62.4 | 55.6 | 46.5 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 97.2 | 118.4 | 153.2 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 3986.9 | 4052.3 | 3571 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 977.2 | 993.4 | 788.6 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 1345.8 | 1362.3 | 3382.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 33.3 | 37.4 | 32.2 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 18.9 | 20.4 | 22.9 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 330.6 | 6.5 | 4.6 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 41.2 | 45.5 | 23.2 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 22 | 24.8 | 24.5 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 2728 | 2800.1 | 4493.7 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1943.9 | 2027.2 | 1667.2 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 373.2 | 271.5 | 28 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 189.6 | 102.7 | 57.3 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 4301.7 | 4218.4 | 3165.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6808.5 | 6619.8 | 4918.3 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 9793.1 | 9628.6 | 9662.2 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 256.6 | 208.7 | 250.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 7065 | 6828.5 | 5168.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 343.8 | 347.4 | 223 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 1367.8 | 1387.1 | 3382.5 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | 468.6 | 762.5 | 1606.1 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 268.4 | 374 | 220.6 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 243.5 | 247.3 | 231.6 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 31.5 | 6 | -6.4 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -117.1 | -338.6 | 74.8 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 95 | -609.8 | 348.1 | |||||||||||||||||
cash-flows.row.inventory | 0 | -97 | -92.3 | 150.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | -108.3 | 372.6 | -430.6 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.8 | -9.1 | 6.4 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 171.3 | 178.4 | 215 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 1.6 | -295.5 | 566.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -12.4 | -1719.6 | -1516.5 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 51 | 1523.6 | 1494.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0.5 | 0.9 | 1.7 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -118 | -744.3 | 408 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2019.5 | -4257 | -3561.4 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 86.2 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | -86.2 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -168.4 | -230.3 | -197.6 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1998.4 | 3576.7 | 3171.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -189.4 | -910.6 | -587.2 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 2.3 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 283.4 | -1196.9 | 565.2 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 797 | 513.7 | 1710.6 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 513.7 | 1710.6 | 1145.4 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 590.8 | 458 | 742.1 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -158.8 | -253.8 | -138.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 432 | 204.2 | 604 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 6350 | 6471.9 | 5845.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 5133.1 | 5119.4 | 4593.5 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 1217 | 1352.5 | 1252.1 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 836.4 | 787.1 | 802.1 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5969.5 | 5906.5 | 5395.7 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 13.5 | 14 | 15.4 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 292 | 297.8 | 268.3 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -114.4 | -30.4 | -162.5 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 51.8 | 100.2 | 99.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 243.5 | 347.7 | 231.6 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | 427.8 | 451.5 | 429.9 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 313.4 | 421.1 | 267.5 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 45 | 47.2 | 46.9 | |||||||||||||||||
income-statement-row.row.net-income | 0 | 224.5 | 374 | 173.5 |
Dažnai užduodami klausimai
Kas yra Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) bendras turtas?
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) bendras turtas yra 9793091573.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.190.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.334.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.037.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.053.
Kas yra Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 224479086.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 1367777175.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 836448131.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 0.000.